Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

The acceptability of biosimilars is certainly higher in the domestic market. Biosimilar substitution is automatic, which can take place as soon as a biosimilar is launched. The choice of a ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

It has been cleared with interchangeable status, meaning that pharmacists in the US will be able to substitute the biosimilar for Soliris at the point of dispensing, without consulting the prescriber.

Alvotech and Teva's product is the first biosimilar to the blockbuster arthritis ... or exon 21 L858R (L858R) substitution mutations. Earlier this month, J&J touted an overall survival win from ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

If you'd like to make a few healthier changes without sacrificing flavor, then here are a couple of alternatives to heavy cream that you can substitute in your recipe. Here are five great ways to ...

The Mexican government recently launched the Mexico Plan (Plan México), a six-year strategy in collaboration with the federal government and ...

Organon & Co (OGN) reported its financial results for the fourth quarter of 2024, revealing stable revenue figures in line with forecasts and a slight miss on earnings per share (EPS). Despite this, ...

The availability of regulatory pathways to register biosimilar antibodies might be another way to decrease healthcare costs and to generalize the use of monoclonal antibodies. As an alternative to ...

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial ...